Duration of dual antithrombotic therapy in patients with NSTE-ACS in sinus rhythm - Summary of recommendations and evidence
After NSTE-ACS, DAPT should be continued for 12 months, regardless of the clinical strategy (angioplasty, myocardial revascularization surgery, or clinical treatment).	I	A
In patients with NSTE-ACS and increased risk of bleeding, DAPT should be continued for only 6 months, with the P2Y12 inhibitor suspended after this period, regardless of the clinical strategy (angioplasty, coronary artery bypass surgery, or clinical treatment)	IIa	B
In NSTE-ACS patients undergoing PCI, DAPT may be considered for 3 months, followed by P2Y12 inhibitor monotherapy (preferably ticagrelor).	lla	A
Associate a second antithrombotic medication (see table below) with ASA after 12 months of DAPT in patients with a high ischemic risk and a low risk of bleeding.	IIa	A